Der Software Biotech-Hammer 500%% chance

wer nicht will hat schon,Risiko wie immer gegeben, aber chancen überwiegen, denke ne KGV von unter 10 sollte 2004 drinn sein.

würde limmitiert in USA kaufen und ein limmit bei ca. 6us$ versuchen.Oder jetzt rein und abwarten.

gruß Grenke

P.S ach ja es geht sich um Simulations Plus WKN 2122560 oder Deutschland WKN 924294  

 

 

doch ist der Anstieg schon ganz schön heftig.
Werde Informationen zu dem Wert sammeln.
Vielleicht gibt es ja ein 30ger retracement, bevor der Biotchindex in USA richtig abgeht.
Dann wäre das Baby bestimmt voll dabei.

cu Byblos  

erwarte einen gesteigerten Umsatz bei leicht rücklaüfigen Ergebnis ( Kostensteigerung durch investition).


gruß Grenke  

Press Release Source: Simulations Plus, Inc. On Thursday June 2, 2011, 8:00 am EDT

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ:SLP - News), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its third fiscal quarter of fiscal year 2011, ended May 31, 2011 (3QFY11).

Ms. Momoko Beran, chief financial officer of Simulations Plus, stated: “In accordance with our policy to release timely financial information to our shareholders, we are releasing preliminary revenues for 3QFY11. Net income will not be known until income taxes have been determined and our auditors review our Quarterly Report on Form 10Q for 3QFY11. We expect to file our 10Q with the U.S. Securities and Exchange Commission on or before the July 15, 2011 deadline.”

Preliminary results for the quarter:

   This was the Company’s 15th consecutive profitable quarter
   Preliminary revenues for the pharmaceutical software and services portion of the business increased to $2.643 million, compared to $2.325 million in 3QFY10
   This represents an increase of 13.7% over 3QFY10
   Approximately 14.3% of 3QFY11 pharmaceutical software and services business was from new customers
   Preliminary revenues for the Words+ subsidiary were $0.800 million compared to $0.794 million in 3QFY10, an increase of 0.8%
   Consolidated preliminary revenues for 3QFY11 were $3.442 million compared to $3.119 million in 3QFY10
   This represents an increase of 10.4% compared to 3QFY10
   Cash at the end of the quarter was $9.7 million

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “We continue to expand our customer base, with over 30 new software customers added so far this fiscal year, including two in China. The increase in adoption of simulation and modeling software by smaller companies demonstrates the trend we’ve been seeing in recent years that the market for simulation and modeling software has potential well beyond the giants of the industry who were the early adopters. We believe the total potential market may be on the order of 1,000-2,000 companies in the pharmaceutical industry alone. In addition to our new software customers, we’ve also added consulting customers. We offer world-class expertise in drug absorption, pharmacokinetics, and pharmacodynamics to our consulting customers, who range from top 5 pharma companies to numerous smaller companies worldwide. We’ve been steadily interviewing and hiring to expand our Life Sciences staff, with one new Ph.D. starting yesterday and another starting August 1. We will continue this expansion for the foreseeable future in order to address a number of market opportunities we’ve identified for organic growth.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. Our wholly owned subsidiary, Words+, Inc., provides assistive technologies to persons with disabilities, including the computerized communication system used by world-famous theoretical astrophysicist Professor Stephen Hawking. For more information, visit our Web sites at www.simulations-plus.com and www.words-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

Contact:

Simulations Plus Investor Relations
Ms. Renée Bouché, 661-723-7723
renee@simulations-plus.com
or
Hayden IR
Mr. Cameron Donahue, 651-653-1854
cameron@haydenir.com